Engineered botulinum neurotoxin

Patent metadata

Field	Value
Publication number	US-10190110-B2
Application number	US-201715431694-A
Country	US
Kind code	B2
Filing date	Feb 13, 2017
Priority date	May 30, 2012
Publication date	Jan 29, 2019
Grant date	Jan 29, 2019

Abstract

Disclosed herein are botulinum neurotoxin (BoNT) polypeptides with a modified receptor binding domain of Clostridial botulinum serotype B (B-H c ), comprising one or more substitution mutations corresponding to substitution mutations in serotype B, strain 1, V1118M; Y1183M; E1191M; E1191I; E1191Q; E1191T; S1199Y; S1199F; S1199L; S1201V; or combinations thereof. Specific combination mutations include E1191M and S1199L, E1191M and S1199Y, E1191M and S1199F, E1191Q and S1199L, E1191Q and S1199Y, or E1191Q and S1199F. Other substitution mutations are also disclosed. Isolated modified receptor binding domains, chimeric molecules, pharmaceutical compositions, and methods of using the same are also disclosed.

First claim

What is claimed:

1. A nucleic acid comprising a nucleotide sequence that encodes a polypeptide comprising a modified receptor binding domain of Clostridial botulinum serotype B, wherein the modified receptor binding domain comprises an amino acid substitution of M, Q, T or I at the amino acid position E1191 of the polypeptide of SEQ ID NO: 4, wherein the substitution produces enhanced binding of the modified receptor binding domain to human Syt II as compared to an identical molecule lacking the substitution.

2. The nucleic acid of claim 1 further comprising a vector nucleotide sequence.

3. A cell comprising a nucleotide sequence that encodes a polypeptide comprising a modified receptor binding domain of Clostridial botulinum serotype B, wherein the modified receptor binding domain comprises an amino acid substitution of M, Q, T or I at the amino acid position E1191 of the polypeptide of SEQ ID NO: 4, wherein the substitution produces enhanced binding of the modified receptor binding domain to human Syt II as compared to an identical molecule lacking the substitution.

4. The cell of claim 3 that expresses the polypeptide.

5. A method to produce a botulinum neurotoxin (BoNT) polypeptide, the method comprising the steps of culturing a cell that expresses a BoNT polypeptide comprising a modified receptor binding domain of Clostridial botulinum serotype B, wherein the modified receptor binding domain comprises an amino acid substitution of M, Q, T or I at the amino acid position E1191 of the polypeptide of SEQ ID NO: 4, wherein the substitution produces enhanced binding of the modified receptor binding domain to human Syt II as compared to an identical molecule lacking the substitution, under conditions wherein said BoNT polypeptide is produced.

6. A method for treating a condition in a subject associated with unwanted neuronal activity comprising administering a therapeutically effective amount of a polypeptide encoded by the nucleic acid of claim 1 .

7. The method of claim 6 wherein the condition is selected from the group consisting of spasmodic dysphonia, spasmodic torticollis, laryngeal dystonia, oromandibular dysphonia, lingual dystonia, cervical dystonia, focal hand dystonia, blepharospasm, strabismus, hemifacial spasm, eyelid disorder, cerebral palsy, focal spasticity and other voice disorders, spasmodic colitis, neurogenic bladder, anismus, limb spasticity, tics, tremors, bruxism, anal fissure, achalasia, dysphagia and other muscle tone disorders and other disorders characterized by involuntary movements of muscle groups, lacrimation, hyperhydrosis, excessive salivation, excessive gastrointestinal secretions, secretory disorders, pain from muscle spasms, headache pain, and dermatological or aesthetic/cosmetic conditions.

8. The nucleic acid of claim 1 , wherein the nucleotide sequence encodes a botulinum neurotoxin (BoNT) polypeptide comprising:
a) a protease domain;
b) a protease cleavage site;
c) a translocation domain; and
d) the modified receptor binding domain of Clostridial botulinum serotype B.

9. The nucleic acid of claim 1 , wherein the modified receptor binding domain comprises two substitutions.

10. The nucleic acid of claim 1 , wherein the substitution is a non-naturally occurring amino acid.

11. The nucleic acid of claim 8 , wherein the protease domain, translocation domain, and protease cleavage site are from serotype selected from the group consisting of A, B, C, D, E, F, G, and combinations thereof.

12. The nucleic acid of claim 11 , wherein the protease domain, translocation domain, and protease cleavage site are from serotype B, strain 1.

13. The nucleic acid of claim 11 , wherein the protease domain, translocation domain, and protease cleavage site are from serotype A, strain 1.

14. A composition comprising the nucleic acid of claim 1 .

15. A nucleic acid comprising a nucleotide sequence that encodes a chimeric molecule comprising a first portion linked to a second portion, wherein the first portion is a modified receptor binding domain of Clostridial botulinum serotype B, wherein the modified receptor binding domain comprises an amino acid substitution of M, Q, T or I at the amino acid position E1191 of the polypeptide of SEQ ID NO: 4.

16. A composition comprising the nucleic acid of claim 15 .

17. A kit comprising a composition comprising the nucleic acid of claim 15 .

18. A method of producing a polypeptide comprising a modified receptor binding domain of Clostridial botulinum serotype B comprising steps of:
expressing the nucleic acid of claim 1 so that the polypeptide is produced.

19. The method of claim 18 , wherein the step of expressing comprises:
administering the nucleic acid to a subject suffering from a condition associated with unwanted neuronal activity so that the nucleic acid is expressed and the polypeptide is produced in cells of the subject.

20. The method of claim 18 , further comprising a step of:
administering the produced polypeptide to a subject suffering from a condition associated with unwanted neuronal activity.

21. The nucleic acid of claim 1 , wherein the modified receptor binding domain further comprises an amino acid substitution of a hydrophobic amino acid at one or more positions corresponding to a position of the polypeptide of SEQ ID NO: 4 that is selected from the group consisting of Y1181, P1197, A1196, F1204, F1194, P1117, W1178, Y1183, V1118, S1116, K1113, K1192, S1199, S1201, E1191, E1245, and Y1256.

22. The nucleic acid of claim 9 , wherein the two substitutions correspond to:
E1191M and S1199Y;
E1191M and S1199L;
E1191M and S1199F;
E1191M and S1201V;
E1191M and Y1183M;
E1191M and V1118M;
E1191Q and S1199Y;
E119 1 Q and S1199L; or
E1191Q and S1199F.

Assignees

• Harvard College

Inventors

• Dong Min
• Peng Lisheng
• Stenmark Pål Erik Gustav
• Berntsson Ronnie Per Arne

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P27/02

  Ophthalmic agents · CPC title

• A61P25/14

  for treating abnormal movements, e.g. chorea, dyskinesia · CPC title

• A61P25/08

  Antiepileptics; Anticonvulsants · CPC title

• A61P25/04

  Centrally acting analgesics, e.g. opioids · CPC title